KR100816264B1 - Cosmetic composition for alleviating skin irritation containing throat extract as an active ingredient - Google Patents
Cosmetic composition for alleviating skin irritation containing throat extract as an active ingredient Download PDFInfo
- Publication number
- KR100816264B1 KR100816264B1 KR1020060079161A KR20060079161A KR100816264B1 KR 100816264 B1 KR100816264 B1 KR 100816264B1 KR 1020060079161 A KR1020060079161 A KR 1020060079161A KR 20060079161 A KR20060079161 A KR 20060079161A KR 100816264 B1 KR100816264 B1 KR 100816264B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- skin irritation
- cosmetic
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000002537 cosmetic Substances 0.000 title claims abstract description 50
- 206010040880 Skin irritation Diseases 0.000 title claims abstract description 27
- 231100000475 skin irritation Toxicity 0.000 title claims abstract description 27
- 230000036556 skin irritation Effects 0.000 title claims abstract description 27
- 239000004480 active ingredient Substances 0.000 title claims abstract description 9
- 241000722953 Akebia Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 238000009472 formulation Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000006071 cream Substances 0.000 claims description 18
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 239000013589 supplement Substances 0.000 abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 12
- 231100000321 erythema Toxicity 0.000 description 12
- 239000004310 lactic acid Substances 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 12
- -1 pack Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 229960000458 allantoin Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002845 discoloration Methods 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940079894 benzophenone-9 Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007933 dermal patch Substances 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000034874 Product colour issue Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/044—Suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 목통 (Akebia quinata) 추출물을 유효 성분으로 포함하는 피부자극 완화용 화장료 조성물을 제공한다. 본 발명의 목통 추출물은 피부자극을 현저히 완화시켜 주고, 또한 증가된 항염증 활성을 갖으며, 화장료에 사용하였을 경우 탁월한 피부자극 완화 효과가 있어 화장품의 보조제로도 유용하다.The present invention is a neck ( Akebia It provides a cosmetic composition for alleviating skin irritation comprising a quinata extract as an active ingredient. The throat extract of the present invention significantly relieves skin irritation, has an increased anti-inflammatory activity, and when used in cosmetics, it has an excellent skin irritation relieving effect and is also useful as a cosmetic supplement.
목통 추출물, 피부자극 완화, 화장료 조성물, 보조제 Throat extract, skin irritation relief, cosmetic composition, supplement
Description
본 발명은 피부자극 완화용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for skin irritation relief.
화장품은 피부를 청결히 하고 건강한 상태를 유지하며 미화를 위해 사용하는 것이나, 화장료 조성물에는 이와 같은 목적과는 상반되는 제품 제조 및 유지에 필수적인 성분들이 포함된다. 이들은 방부제, 계면활성제, 자외선 차단제, 미백제 등 화장료의 보존, 유지 및 기능을 부여하기 위하여 필수 불가결하게 첨가되는 성분들로 실제로 제품 사용시에 일부에서 피부 자극을 유발하기도 한다. 따라서, 화장품 제조업자들은 일반적으로 사용되는 자극 완화 물질을 제품에 적용시켜줌으로써 그 자극을 최소화시키기 위한 노력을 진행하고 있다.Cosmetics are used for cleansing, maintaining a healthy state and beautifying the skin, but the cosmetic composition includes ingredients necessary for the manufacture and maintenance of the product contrary to this purpose. These are ingredients that are indispensable for preserving, maintaining, and functioning cosmetics such as preservatives, surfactants, sunscreens, and whitening agents, and may cause skin irritation in some of the products actually used. Therefore, cosmetics manufacturers are making efforts to minimize the irritation by applying commonly used irritant substances to the product.
화장품의 사용에 의해 일어날 수 있는 피부 자극에는 가려움 (itching), 따끔거림 (stinging) 및 화끈거림 (burning)등의 자극감과 홍반 (erythema) 및 부종 (edema) 등이 있다. 이러한 자극들은 염증 반응의 현상으로 염증을 경감시키거나 제거시키는 작용을 하는 것을 항염제라 한다. 현재까지 항염의 목적으로 이용되고 있는 물질로는 비스테로이드계로서 플루페나믹산(flufenamic acid), 이부프로펜(ibuprofen), 벤지다민(benzydamine), 인도메타신(indometacine)등이 있고, 스테로이드 계통으로 프레드니솔론(prednisolone), 덱사메타손(dexamethasone) 등이 있으며(김창종, 병태생리학, 한림상사, p61-69, 1988), 알란토인, 아즈렌, ε-아미노키프론산, 하이드로코티존(v), 감초산 및 그 유도체(β-글리칠레친산, 글리칠레친산유도체) 등이 항염증에 효과가 있는 것으로 알려져 있으나(광정무부, 신화장품학, 남산당, p162, 1993), 인도메타신은 화장료에는 사용할 수 없는 물질이고 하이드로코티존은 사용량이 제한되어 있으며, 감초산 및 그 유도체는 안정화시키기 어렵거나 용해도가 좋지않아 실제 적용시 농도의 제한으로 인하여 실질적인 효과를 거두기가 어려운 문제점을 가지고 있다.Skin irritation that may occur with the use of cosmetics includes irritation such as itching, stinging and burning, and erythema and edema. These stimuli are called anti-inflammatory drugs that act to alleviate or eliminate inflammation as a phenomenon of the inflammatory response. To date, non-steroidal substances that are used for anti-inflammatory purposes include flufenamic acid, ibuprofen, benzydamine, indomethacin, and prednisolone as a steroid system. prednisolone) and dexamethasone (Kim Chang-jong, Pathophysiology, Hallym Co., p61-69, 1988), allantoin, azulene, ε-aminokiproic acid, hydrocortisone (v), licoriceic acid and its derivatives (β) -Glycylinic acid, Glychilechin acid derivatives, etc. are known to be effective in anti-inflammatory (Ministry of Justice, Department of New Cosmetics, Namsan Sugar, p162, 1993), but indomethacin cannot be used in cosmetics and hydrocortisone This is limited, licorice acid and its derivatives are difficult to stabilize or poor solubility is difficult to achieve a practical effect due to the limitation of concentration in actual application It has a point.
본 발명자들은 상기와 같은 단점을 보완하기 위하여 천연물을 대상으로 예의 연구를 수행한 결과 목통 추출물이 제형의 안정화가 쉽고 화장품에 의한 부작용을 줄이고 피부자극을 완화하는 효과를 갖는 물질임을 발견하여 본 발명을 완성하였다.The present inventors conducted a thorough study on natural products in order to compensate for the above disadvantages, and found that the neck extract is a substance having an effect of stabilizing the formulation, reducing side effects caused by cosmetics, and alleviating skin irritation. Completed.
따라서, 본 발명의 목적은 목통 추출물을 유효 성분으로 포함하는 피부자극 완화용 화장료 조성물을 제공하는 데 있다.Therefore, it is an object of the present invention to provide a cosmetic composition for skin irritation relief comprising the extract of the throat as an active ingredient.
본 발명의 다른 목적 및 이점은 하기의 실시예 및 청구범위에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become apparent from the following examples and claims.
본 발명의 다른 일 양태에 따르면, 본 발명은 목통 추출물을 유효 성분으로 포함하는 피부자극 완화용 화장료 조성물을 제공한다.According to another aspect of the present invention, the present invention provides a cosmetic composition for alleviating skin irritation, comprising a throat extract as an active ingredient.
본 발명의 유효 성분으로 이용된 목통은 으름덩굴과에 속하는 다년생 덩굴나무인 으름덩굴(Akebia quinata)의 줄기부분을 건조한 것으로 한의에서 소염약, 이뇨약, 진통약, 배농약으로 신장염, 심장병으로 인한 부기, 신경통, 관절염, 임신부기에 쓰인다. The barrel used as an active ingredient of the present invention is a perennial vine belonging to the ivy ( Akebia) quinata ) is a dry stem, used as an anti-inflammatory, diuretic, analgesic, and pear pesticide in oriental medicine. It is used for nephritis, heart disease, swelling, neuralgia, arthritis, and pregnancy.
상기 목통추출물은 다양한 추출 용매, 예를 들어, 물, 탄소수 1-4의 무수 또는 함수 저급 알코올 (메탄올, 에탄올, 프로판올 및 부탄올), 아세톤, 에틸 아세테이트, 클로로포름, 1,3-부틸렌글리콜 및 부틸 아세테이트로 구성된 군으로부터 선택되는 추출 용매로 하여 목통으로부터 얻을 수 있다. 보다 바람직하게는, 본 발명의 추출물은 함수 저급 알코올, 가장 바람직하게는 에탄올을 이용하여 얻어진 것이다. 한편, 본 발명의 추출물은 상기한 추출 용매 뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다.The neck extract can be a variety of extraction solvents, such as water, anhydrous or hydrous lower alcohols (methanol, ethanol, propanol and butanol) having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, 1,3-butylene glycol and butyl It can be obtained from the barrel as an extraction solvent selected from the group consisting of acetate. More preferably, the extract of the present invention is obtained using a hydrous lower alcohol, most preferably ethanol. On the other hand, it will be apparent to those skilled in the art that the extract of the present invention can be obtained extracts having substantially the same effect using not only the above-described extraction solvent but also other extraction solvents.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물 뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함되는 것이다.In addition, the extract of the present invention includes not only the extract by the above-mentioned extraction solvent, but also the extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The active fraction is also included in the extract of the present invention.
본 발명의 바람직한 구현예에 따르면, 상기 추출물의 함량은 화장료 조성물 총 중량에 대하여 0.001-5.0 중량%이다. 상기 함량 미만일 경우에는 기대효과가 나타나기 어렵고, 상기 함량을 초과하는 경우에는 효과가 더 이상 증가하지 않는다.According to a preferred embodiment of the present invention, the content of the extract is 0.001-5.0% by weight relative to the total weight of the cosmetic composition. If the content is less than the expected effect is difficult to appear, if the content is exceeded the effect is no longer increased.
본 발명의 목통 추출물은 외부 물질에 의한 피부자극을 완화하고 항염증 활성이 있으며, 화장품 원료에 의한 피부자극을 완화한다. 따라서, 본 발명의 목통 추출물은 화장품 원료에 의한 피부자극을 완화하는 화장품 보조제로서 사용될 수 있다.Throat extract of the present invention to alleviate the skin irritation caused by external substances and has an anti-inflammatory activity, to mitigate the skin irritation caused by cosmetic raw materials. Therefore, the throat extract of the present invention can be used as a cosmetic supplement to alleviate skin irritation caused by cosmetic raw materials.
상기 화장료 조성물에서 피부자극을 일으키는 원료는 천연 추출물 및 화장료에 통상적으로 사용될 수 있는 성분을 포함한다. 피부자극을 일으키는 대표적인 원료로는 락틱산 (lactic acid), 글리콜릭산 (glycolic acid), 살리실산 (salicylic acid) 및 레티노산 (retinoic acid)이 있으나 이에 한정되는 것은 아니다. Raw material causing skin irritation in the cosmetic composition includes a natural extract and ingredients that can be commonly used in cosmetics. Representative raw materials that cause skin irritation include, but are not limited to, lactic acid, glycolic acid, salicylic acid and retinoic acid.
본 발명의 화장료 조성물은 목통 추출물을 유효 성분으로 포함하는 조성물로서 제조되어, 피부 자극성이 큰 화장료 조성물을 피부에 적용하기 전 또는 적용한 후에 적용될 수 있다. 또한, 목통 추출물을 피부 자극성이 큰 화장료 조성물에 추가적으로 첨가시켜 피부에 적용될 수도 있다.The cosmetic composition of the present invention is prepared as a composition comprising a neck extract as an active ingredient, and may be applied before or after applying the cosmetic composition having a large skin irritation to the skin. In addition, the extract may be applied to the skin by additionally added to the cosmetic composition having a high skin irritation.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서 상기 목통 추출물 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to the neck extract as an active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, And carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art and include, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명은 화장품을 피부에 도포하였을 때 발생할 수 있는 피부자극을 목통 추출물을 이용하여 완화시켜줌으로써 화장품의 피부 안전성을 증진시킨다.The present invention improves skin safety of cosmetics by relieving skin irritation that may occur when cosmetics are applied to the skin by using a throat extract.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it is to those of ordinary skill in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. Will be self-evident.
제조예 1. 목통 추출물의 제조Preparation Example 1 Preparation of Bark Extract
목통을 정제수로 세척한 후 건조하고 작은 조각으로 파쇄한 뒤, 여기에 그 건조 중량의 1-10배의 70% 저급알코올을 가하였다. 15-35℃에서 5일간 추출한 후 300메쉬 여과포로 여과하고, 다시 와트만 5번 여과지로 여과한 후, 회전 감압증발기로 건조하여, 건조 중량 63 g/㎏을 얻었다. 건조된 목통 추출 파우더를 30% 1,3-부틸렌 글리콜에 용해하여 사용하였다.The neck was washed with purified water and then dried and broken into small pieces, to which 70% lower alcohol, 1-10 times its dry weight, was added. The mixture was extracted at 15-35 ° C. for 5 days, filtered through a 300 mesh filter cloth, filtered through Whatman No. 5 filter paper, and then dried using a rotary evaporator to obtain a dry weight of 63 g / kg. The dried neck extract powder was used dissolved in 30% 1,3-butylene glycol.
실험예 1: 목통 추출물의 락틱산에 의한 세포자극의 완화 효과 시험Experimental Example 1 Test of the Relaxation Effect of Cellulose Extracts by Lactic Acid
인간 피부세포인 섬유아세포 (한국세포주은행)를 T-75 플라스크 (Falcon, 미합중국)에서 90%정도 성장할 때까지 배양하였다. 이것을 다시 96-웰 플레이트 (Falcon, 미합중국)에 3 × 104 세포/웰이 되게 옮겨 24시간 배양하였다. 배양 후 현미경을 통해 세포가 완전히 부착되어 잘 자라는지 여부를 확인하고 피부세포 자극원으로 락틱산을 이용하여 실험을 진행하였다. 이때 락틱산은 0.2% (이 농도에서 피부세포는 모두 사멸함)로 사용하였다. 즉, 96웰 플레이트의 각웰에 0.2% 락틱산이 함유된 DMEM (시그마, 미합중국) 배지를 200 ㎕씩 첨가하고 목통 추출물을 10, 20, 50, 100 및 200 ㎍/㎖로 조절하여 첨가하였다. 이때, 대조군에는 락틱산 및 추출물을 첨가하지 않았으며 비교군으로는 락틱산만 첨가한 것을 사용하였다. 시험 물질을 첨가하고 12시간 경과 후 세포의 생존율을 비교하기 위하여 MTT 시약을 각 웰에 10 ㎕씩 첨가하였다.Fibroblasts (Korea Cell Line Bank), which are human skin cells, were cultured in T-75 flasks (Falcon, USA) until 90% growth. This was again transferred to 96 × well plates (Falcon, USA) to 3 × 10 4 cells / well and incubated for 24 hours. After culturing, the microscope confirmed whether the cells were completely attached and grew well. The experiment was performed using lactic acid as a source of skin cell stimulation. At this time, lactic acid was used as 0.2% (all skin cells were killed at this concentration). That is, 200 μl of DMEM (Sigma, US) medium containing 0.2% lactic acid was added to each well of a 96 well plate, and the neck extract was adjusted to 10, 20, 50, 100 and 200 μg / ml. In this case, no lactic acid and extract were added to the control group, and only the lactic acid was added as a comparative group. Twelve μl of MTT reagent was added to each well to compare cell viability after 12 hours of addition of test material.
4시간 경과 후에 세포 생존율을 알아보기 위해, 엘라이저 리더(ELISA reader)를 이용하여 570 nm 파장에서 흡광도를 측정하고 하기 수학식 1에 따라 세포 생존율을 계산하고, 그 결과를 표 1에 기재하였다.In order to determine the cell viability after 4 hours, absorbance at 570 nm was measured using an ELISA reader, and cell viability was calculated according to Equation 1 below, and the results are shown in Table 1.
상기 표 1의 결과를 보면, 락틱산 처리된 세포에 목통 추출물을 처리한 경우 추출물 처리 농도 의존적으로 세포의 생존율이 증가하여, 락틱산에 의한 세포자극을 목통 추출물이 완화시켜 줌을 알 수 있었다.In the results of Table 1, it was found that when the neck extract was treated to the lactic acid treated cells, the survival rate of the cells increased depending on the concentration of the extract, and the neck extract was relieved of cell stimulation caused by the lactic acid.
실험예Experimental Example 2 : 목통 추출물의 항염증 효과 시험 2: anti-inflammatory effect test of neck extract
목통 추출물의 항염증 효과를 측정하기 위해서 평소 피부병 내지는 피부 알레르기 증상이 없는 사람 20명을 대상으로 항염증 효과를 측정하였다. 연령분포는 21-35세이고 평균연령은 29세였다. 시험방법은 다음과 같이 하였다. 팔 상박에 3군데 측정 위치를 표지한 후 chromameter로 피부의 홍반(a* value)을 측정하였다. 2군데 측정 위치에 5% 목통 추출물(실험군)과 감초산(비교군, 기존의 항염증제)을 각각 1시간 간격으로 4회 적용하고 나머지 한 군데(대조군)는 적용하지 않았다. 마지막 적용 20-30분 경과 후 측정 위치를 흐르는 물에 가볍게 닦아내었다.In order to measure the anti-inflammatory effect of the neck extract, the anti-inflammatory effect was measured in 20 people with no skin disease or skin allergy symptoms. The age distribution was 21-35 years old and the average age was 29 years old. The test method was as follows. After measuring three measurement locations on the upper arm, the erythema (a * value) of the skin was measured with a chromameter. 5% neck extract (experimental group) and licoriceic acid (comparative group, conventional anti-inflammatory agent) were applied 4 times at 1 hour intervals in two measurement locations, and the other one (control) was not applied. After 20-30 minutes of last application, the measurement site was lightly wiped with running water.
상박에 물이 다 마르면 3 mM 메틸 니코티메이트(methyl nicotimate, 0.04%)를 페이퍼 디스크에 80 ㎕를 덜어 흠뻑 적신 후 1분 30초 동안 올려 놓았다. 1분 30초 경과 후 페이퍼 디스크를 제거한 후 흐르는 물에 씻어 내었다. 20-30분 후 염증이 유발되면 홍반이 생기는데 이 홍반의 발생 정도를 chromameter로 측정하여 실험 초기의 홍반 정도와 비교하여 홍반 억제 정도를 평가하였다. 항염증 효과 평가는 하기 수학식 2와 같이 하여 그 결과를 표 2에 나타내었다.When the water was dried on the upper arm, 3 mM methyl nicotimate (0.04%) was soaked in 80 μl of paper disk, and placed for 1 minute and 30 seconds. After 1 minute and 30 seconds, the paper disk was removed and washed with running water. After 20-30 minutes of inflammation, erythema develops. The incidence of erythema is measured by chromatometer and the degree of erythema suppression is evaluated by comparing with erythema at the beginning of the experiment. Evaluation of the anti-inflammatory effect was performed as in Equation 2 below, and the results are shown in Table 2.
상기 표 2의 실험결과를 통해, 기존의 항염증제인 감초산에 비하여 본 발명의 목통 추출물의 항염증 효과가 훨씬 더 뛰어남을 알 수 있다.Through the experimental results of Table 2, it can be seen that the anti-inflammatory effect of the neck extract of the present invention is far superior to the conventional anti-inflammatory licorice.
상기 실험예를 근거로 피부자극 완화 효과가 우수한 목통 추출물을 함유하는 여러 가용화제형과 유화제형의 화장료 조성을 제시한다. 아래와 같은 제형예에서 이를 상세히 설명하지만 본 발명의 조성물이 하기 예에만 한정되는 것은 아니다.On the basis of the experimental example, it proposes a cosmetic composition of various solubilizing agent type and emulsifier type containing a throat extract excellent in skin irritation relief effect. Although this is described in detail in the following formulation example, the composition of the present invention is not limited only to the following examples.
제형예 1: 유연화장수 (스킨로션)Formulation Example 1: Softener (Skin Lotion)
하기의 표 3과 같이 목통 추출물을 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.As shown in Table 3 below, the softening lotion containing the barrel extract was prepared according to a conventional method.
제형예 2. 수렴화장수Formulation Example 2. Converging Cosmetic Water
하기의 표 4와 같이 목통 추출물을 함유하는 수렴화장수를 통상의 방법에 따라 제조하였다.As shown in Table 4 below, astringent cosmetic water containing a throat extract was prepared according to a conventional method.
제형예 3. 영양화장수Formulation Example 3. Nutrients
하기의 표 5와 같이 목통 추출물을 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.As shown in Table 5, nutritious longevity containing the neck extract was prepared according to a conventional method.
제형예 4. 영양크림Formulation Example 4. Nutrition Cream
하기의 표 6과 같이 목통 추출물을 함유하는 영양크림을 통상의 방법에 따라 제조하였다.Nutritious cream containing a throat extract as shown in Table 6 below was prepared according to a conventional method.
제형예 5. 맛사지 크림Formulation Example 5. Massage Cream
하기의 표 7과 같이 목통 추출물을 함유하는 맛사지 크림을 통상의 방법에 따라 제조하였다.A massage cream containing a throat extract as shown in Table 7 below was prepared according to a conventional method.
제형예 6. 에센스Formulation Example 6. Essence
하기의 표 8과 같이 목통 추출물을 함유하는 에센스를 통상의 방법에 따라 제조하였다.Essence containing the throat extract as shown in Table 8 below was prepared according to a conventional method.
제형예 7. 팩Formulation Example 7 Pack
하기의 표 9와 같이 목통 추출물을 함유하는 팩을 통상의 방법에 따라 제조하였다.As shown in Table 9 below, a pack containing a barrel extract was prepared according to a conventional method.
실험예 3: 인체 피부 첩포시험Experimental Example 3: Human Skin Patch Test
과거력상 피부자극에 과민반응을 보인 적이 없으며, 현재 피부병 내지 피부 알러지 증상이 없는 20-30대 여성 20명을 대상으로 목통 추출물 5.0 중량%가 함유된 상기 제형예 4의 화장료에 피부 자극 물질인 락틱산 5.0 중량%를 자극원으로 첨가하여(실시예) 인체 피부 첩포시험을 통하여 자극 완화 효과를 확인하였다. 이 때 락틱산 및 목통 추출물을 첨가하지 않은 그룹을 대조군으로 하였고, 제형예 4의 화장료에 포함된 목통 추출물을 정제수로 대체하고 락틱산만 첨가한 것을 비교예 1로 하였으며, 제형예 4의 화장료에 포함된 목통 추출물을 5.0 중량% 감초산으로 대체한 것을 비교예 2로 하였다.Rock, which is a skin irritant in the cosmetic formulation of Formulation Example 4, containing 5.0 wt% of neck extract, targeting 20 women in their 20s and 30s who have never had hypersensitivity to skin irritation due to past history and have no skin disease or skin allergy symptoms. Tic acid 5.0% by weight was added as an irritant (Example), and the irritation-relieving effect was confirmed through a human skin patch test. At this time, the group without addition of the lactic acid and the throat extract was used as a control group, the neck extract included in the cosmetic formulation of Formulation Example 4 was replaced with purified water and only the lactic acid was added as Comparative Example 1, and included in the cosmetic formulation of Formulation Example 4 Comparative Example 2 was used to replace the neck extract extracted with 5.0% by weight licorice.
우선 시험부위를 70% 에탄올로 닦아낸 뒤 건조시켰다. 준비된 시험물질을 15 ㎍씩 핀 챔버 (Finn chamber, 100ㅧ10, EPITEST, 핀란드국) 내에 적하시킨 후 시험대상자의 전박 (forearm) 안쪽 부위에 밀폐첩포하였다. 24시간 동안 첩포하고 첩포를 제거한 후 표시펜으로 시험부위를 표시하였다. 각각 1시간 그리고 24시간 후(첩포 제거 후 1시간, 24시간 후 = 첩포 부착 포함 24시간, 48시간)에 확대경 (8MC-150, DAZOR, 미합중국)을 이용하여 시험 부위를 관찰하여 홍반 및 부종 유무를 관찰하였다.First the test site was wiped with 70% ethanol and dried. 15 μg of the prepared test substance was added dropwise into a Fin chamber (Finn chamber, 100 × 10, EPITEST, Finland), and then airtightly wrapped inside the forearm of the test subject. The patch was applied for 24 hours, the patch was removed, and the test site was marked with a marker pen. 1 hour and 24 hours after each removal (1 hour after removal, 24 hours = 24 hours, 48 hours including patch attachment) using a magnifying glass (8MC-150, DAZOR, United States) to observe the test site for erythema and edema Was observed.
피부반응은 국제접촉피부염연구회 (ICDRG: International Contact Dermatitis Research Group )의 규정에 따라 판정하였으며, 하기 수학식 3에 의하여 평균피부반응도를 계산하고 그 결과를 표 10에 나타내었다.The skin reaction was determined according to the regulations of the International Contact Dermatitis Research Group (ICDRG), and the average skin reactivity was calculated by Equation 3 below and the results are shown in Table 10.
※ 피부 반응의 평가 기준 및 점수 ※ Evaluation criteria and score of skin reaction
상기 표 10의 결과에서 알 수 있듯이, 5.0 중량%의 목통 추출물을 함유하는 실시예는 5.0 중량% 감초산을 함유한 비교예 2에 비해, 락틱산에 의해 유발된 피부자극의 완화 효과가 월등히 우수함을 알 수 있었다.As can be seen from the results of Table 10, the example containing 5.0% by weight of the neck extract is significantly superior to the relaxation effect of the skin irritation induced by lactic acid, compared to Comparative Example 2 containing 5.0% by weight licorice And it was found.
실험예 4 : 목통 추출물을 함유하는 크림의 제형의 안정성 시험Experimental Example 4: Stability test of the formulation of the cream containing the throat extract
본 발명의 화장료 제형의 온도 변화에 따른 안정성을 시험하였다. 목통 추출물을 함유한 상기 제형예 4의 영양크림, 제형예 4에서 목통 추출물을 5.0 중량% 감초산으로 대체한 크림(비교예), 그리고 정제수로 대체한 크림(대조예)을 불투명 초자 용기에 담아 45℃로 일정하게 유지되는 항온조에서 1주 동안 보관하고, 또한 불투명 초자 용기에 담아 4℃로 일정하게 유지되고 완전히 차광 된 냉장고 내에서 1주 동안 보관한 후 변색 정도를 비교 측정하였다. 그 결과는 하기 표 11에 나타나 있다. 이때 제품 변색 정도는 다음의 6등급으로 분류하여 평가하였다.The stability according to the temperature change of the cosmetic formulation of the present invention was tested. Nourishing cream of Formulation Example 4 containing the throat extract, cream (Comparative Example) replacing the neck extract with 5.0 wt% licorice in Formulation Example 4, and the cream (control) replaced with purified water in an opaque glass container After storage for 1 week in a constant temperature bath maintained at 45 ℃, and also kept in a opaque glass jar at a constant 4 ℃ and stored in a completely shaded refrigerator for 1 week, the degree of discoloration was measured. The results are shown in Table 11 below. At this time, the degree of product discoloration was evaluated by classifying into the following six grades.
※ 제품 변색 평가 기준※ criteria for evaluation of product discoloration
상기 표 11의 결과에서 알 수 있는 바와 같이, 목통 추출물 대신 감초산을 함유한 비교예의 크림은 제형의 안정성이 미약하였지만, 목통 추출물을 함유하는 제형예 4의 크림은 변색이 거의 되지 않아 기존의 화장료에 비해 안정성이 매우 우수함을 알 수 있었다. 목통 추출물을 정제수로 대체한 대조예에서는 변색이 일어나지 않은 것으로 보아 크림의 기타 함유 성분에 의해서는 변색이 일어나지 않는다는 것을 알 수 있었다.As can be seen from the results of Table 11, the cream of Comparative Example containing licorice acid instead of the neck extract was weak in the stability of the formulation, the cream of Formulation Example 4 containing the neck extract is hardly discolored, the conventional cosmetics Compared to the stability was found to be very excellent. Discoloration did not occur in the control case where the neck extract was replaced with purified water, indicating that discoloration did not occur by the other ingredients of the cream.
이상에서 상세히 설명하듯이, 본 발명은 목통 추출물을 유효 성분으로 포함하는 피부자극 완화용 화장료 조성물을 제공한다. 본 발명의 목통 추출물은 기존 항염제에 비해 화장품 원료에 의한 피부자극을 현저히 완화시켜 주며, 또한 증가된 항염증 활성을 나타내므로, 화장료에 사용하였을 경우 탁월한 피부자극 완화 효과가 있다. 따라서, 본 발명의 화장료 조성물은 화장품을 피부에 도포하였을 때 발생할 수 있는 피부자극을 목통 추출물을 이용하여 완화시켜줄 수 있기 때문에 화장품의 피부 안전성을 증진시킬 수 있다.As described in detail above, the present invention provides a cosmetic composition for alleviating skin irritation, comprising a throat extract as an active ingredient. The neck extract of the present invention significantly relieves skin irritation by cosmetic raw materials, and also shows an increased anti-inflammatory activity, compared to existing anti-inflammatory agents, and when used in cosmetics, has an excellent skin irritation relief effect. Therefore, the cosmetic composition of the present invention can enhance skin safety of the cosmetic because it can relieve skin irritation that may occur when the cosmetic is applied to the skin by using a neck extract.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060079161A KR100816264B1 (en) | 2006-08-22 | 2006-08-22 | Cosmetic composition for alleviating skin irritation containing throat extract as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060079161A KR100816264B1 (en) | 2006-08-22 | 2006-08-22 | Cosmetic composition for alleviating skin irritation containing throat extract as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080017678A KR20080017678A (en) | 2008-02-27 |
KR100816264B1 true KR100816264B1 (en) | 2008-03-27 |
Family
ID=39384958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060079161A KR100816264B1 (en) | 2006-08-22 | 2006-08-22 | Cosmetic composition for alleviating skin irritation containing throat extract as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100816264B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170003057A (en) | 2015-06-30 | 2017-01-09 | 재단법인 진안홍삼연구소 | A composition comprising akebia quinata extract for preventing, improving or treating inflammation induced virulence of oral bacteria |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001335458A (en) * | 2000-05-29 | 2001-12-04 | Shiseido Co Ltd | Skin care preparation |
JP2001342112A (en) * | 2000-06-02 | 2001-12-11 | Shiseido Co Ltd | Skin care preparation |
-
2006
- 2006-08-22 KR KR1020060079161A patent/KR100816264B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001335458A (en) * | 2000-05-29 | 2001-12-04 | Shiseido Co Ltd | Skin care preparation |
JP2001342112A (en) * | 2000-06-02 | 2001-12-11 | Shiseido Co Ltd | Skin care preparation |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170003057A (en) | 2015-06-30 | 2017-01-09 | 재단법인 진안홍삼연구소 | A composition comprising akebia quinata extract for preventing, improving or treating inflammation induced virulence of oral bacteria |
Also Published As
Publication number | Publication date |
---|---|
KR20080017678A (en) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100844275B1 (en) | Skin anti-aging cosmetic composition containing noni extract as an active ingredient | |
KR100501399B1 (en) | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome | |
KR20140012456A (en) | Composition for improving skin conditions comprising akebia saponin d | |
KR20050122074A (en) | Cosmetic composition comprising torreya nucifera extract as active ingredient for improving skin wrinkle and elasticity | |
KR100955572B1 (en) | Cosmetic composition containing noni supercritical extract | |
KR101668029B1 (en) | Cosmetic Composition for Reducing Skin Wrinkle Comprising Lapachol | |
KR100858628B1 (en) | Cosmetic composition for skin stimulation alleviation comprising soruja extract stabilized with nano liposomes | |
KR20080093500A (en) | Roe deer urine extract | |
KR20050071730A (en) | Cosmetic compostion for alleviating skin irritation comprising mung bean extract stabilized in nanoliposome | |
KR100816264B1 (en) | Cosmetic composition for alleviating skin irritation containing throat extract as an active ingredient | |
KR100816265B1 (en) | Cosmetic composition for alleviating skin irritation containing rhubarb extract as an active ingredient | |
KR100638053B1 (en) | Cosmetic composition for alleviating skin irritation containing Soru-Jin extract as an active ingredient | |
KR20100132206A (en) | Cosmetic composition for improving the appearance of skin comprising ginsenoside Rh2 as an active ingredient | |
KR102181893B1 (en) | Cosmetic and pharmaceutical compositin comprising aloe extract, upland rice extract and ceramide | |
KR20080046793A (en) | Cosmetic composition for improving skin wrinkles containing longan extract as an active ingredient | |
KR20050120880A (en) | Cosmetic composition having skin-irritation reducing effect and containing morinda citrifolia extract | |
KR100946584B1 (en) | Cosmetic composition for astringent and skin irritation containing fruit extract and Blue Lotus extract | |
KR20200073523A (en) | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Lithospermum Erythrorhizon | |
KR102470781B1 (en) | Cosmetic Composition for Reducing Skin Wrinkle | |
KR20080057414A (en) | Cosmetic composition for alleviating skin irritation containing azalea root extract | |
KR100635782B1 (en) | Cosmetic composition for skin irritation relaxation containing peeled black bean extract as an active ingredient | |
KR100928125B1 (en) | Wrinkle improvement cosmetic composition containing metasequoia extract | |
KR100537914B1 (en) | Cosmetic Composition Comprising Calyx Kaki as Active Ingredient for Improving Skin Wrinkle and Elasticity | |
KR20090073632A (en) | Cosmetic composition for alleviating skin irritation containing Yeok wood extract and licorice extract | |
KR20180096094A (en) | A composition for improving skin wrinkle comprising Cosmos bipinnatus extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20060822 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070720 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20080108 |
|
PG1501 | Laying open of application | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080318 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20080318 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20100902 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20110916 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130111 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20130111 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20131127 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20150112 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151211 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20151211 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161227 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20161227 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190109 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20190109 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191226 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20191226 Start annual number: 13 End annual number: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20201222 Start annual number: 14 End annual number: 14 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20221229 |